Real-World Experience of Adults With Acute Myeloid Leukemia on Hypomethylating Agents With or Without Venetoclax at a Comprehensive Cancer Center

BACKGROUND: Venetoclax (VEN) in combination with hypomethylating agent (HMA) therapy is a standard treatment option for patients with newly diagnosed acute myeloid leukemia (AML); however, data are limited in the relapsed or refractory (R/R) populations and in those with poor-risk disease. A retrosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Freeman, Tracelyn, Williams, Kiersten, Puto, Marcin, Waller, Allyson, McLaughlin, Eric M., Blachly, James S., Roddy, Julianna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990729/
https://www.ncbi.nlm.nih.gov/pubmed/36896000
http://dx.doi.org/10.14740/wjon1557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990729/
https://www.ncbi.nlm.nih.gov/pubmed/36896000
http://dx.doi.org/10.14740/wjon1557

Ejemplares similares